When was BioTissue founded?

BioTissue was founded in 2001 and raised its 1st funding round 5 years after it was founded.

Where is BioTissue located?

BioTissue is headquartered in Miami, United States. It is registered at Miami, Florida.

How many employees does BioTissue have?

As of Mar 31, 2026, the latest employee count at BioTissue is 369.

Is BioTissue a funded company?

BioTissue is a funded company, having raised a total of $110M across 18 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 15, 2006.

When was the latest funding round of BioTissue?

BioTissue's latest funding was a $***** Grant (prize money) round on Jun 21, 2021, with participation from 1 investor.

Where does BioTissue rank among its competitors?

BioTissue ranks 439th amongst 2681 active competitors, of which 916 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of BioTissue?

BioTissue's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

BioTissue - 2026 Company Profile, Team, Funding & Competitors

BioTissue is a series C company based in Miami (United States), founded in 2001 by Amy Tseng. It operates as a Developer of regenerative biologic therapies for eye care. BioTissue has raised $110M in funding from investors like Ballast Point Ventures, RC Capital and EW Healthcare Partners. The company has 2681 active competitors, including 916 funded and 671 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Developer of regenerative biologic therapies for eye care. The company offers a range of products that aim to help improve patient outcomes in regenerative wound healing AmnioGraft, Prokera, Neox 1K, and more.

Website: biotissue.com
Social
Phone Number: +1 **********
Registered Address: Miami, Florida

Key Metrics

Founded Year

2001

Location

Miami, United States

Stage

Series C

Total Funding

$110M in 18 rounds

Latest Funding Round

Grant (prize money), Jun 21, 2021, $*****

Investors

Ballast Point Ventures & 3 more

Ranked

439^th among 2681 active competitors

Employee Count

369 as on Mar 31, 2026

Similar Companies

Apellis Pharmaceuticals & 358 more

View BioTissue's full profile

BioTissue is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tissuetech, Inc. CIN: 20131722241 , United States, Deadpooled	Dec 19, 2013	$5M - $25M (As on Oct 10, 2013)	-	-
TISSUE TECH, INC CIN: 651116071 , United States, Active	Dec 31, 1999	-	311 (As on Dec 31, 2024)	-

BioTissue has raised a total funding of $110M over 18 rounds. Its first funding round was on Sep 15, 2006. Its latest funding round was a Grant (prize money) round on Jun 21, 2021 for $*****. 1 investor participated in its latest round. BioTissue has 4 institutional investors.

Here is the list of recent funding rounds of BioTissue:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 21, 2021	7100407	Grant (prize money)	9800938	2636452	2287434	2482245
Apr 12, 2019	4119590	Series C	3524104	6034028	9690644	Ballast Point Ventures
Nov 18, 2016	7589170	Grant (prize money)	4527776	2191176	7979362	HHS

Access funding benchmarks and valuations. Sign up today!

View details of BioTissue's funding rounds and investors

The founders of BioTissue is Amy Tseng.

Here are the details of BioTissue's key team members:

Amy Tseng: Founder and Board Member of BioTissue.

View details of BioTissue's Founder profiles and Board Members

BioTissue's employee count trend

BioTissue has 369 employees as of Mar 26. Here is BioTissue's employee count trend over the years:

Uncover BioTissue's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioTissue include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of BioTissue, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Replimune 2015, Oxford (United Kingdom), Public	Developer of oncolytic immunotherapies	$87M	Foresite Capital, Omega Funds & 7 others	70/100
439th	BioTissue 2001, Miami (United States), Series C	Developer of regenerative biologic therapies for eye care	$110M	Ballast Point Ventures, RC Capital & 2 others	52/100